New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:23 EDTMON, TKMRTekmira signs license option agreement with Monsanto
Tekmira Pharmaceuticals (TKMR) announced that it has signed an Option Agreement with Monsanto (MON), pursuant to which Monsanto may obtain a license to use Tekmira's proprietary delivery technology. The transaction will support the application of Tekmira's proprietary delivery technology and related intellectual property for use in agriculture. Tekmira noted that the potential value of the transaction could reach up to $86.2M following the successful completion of milestones. Tekmira expects to receive a near term payment of net $16.5M. Over the option period, which is expected to be approximately four years, Tekmira will provide lipid formulations to Monsanto's research and development activities, and Monsanto will make certain payments to Tekmira to maintain its option rights. At any time during the option period, Monsanto may choose to exercise its option, in which case Monsanto will pay to Tekmira an option exercise fee and will receive a worldwide, exclusive right to use Tekmira's proprietary delivery technology in the field of agriculture. Monsanto may elect to terminate this option at their discretion. Tekmira retains all rights to therapeutics uses of all current IP and IP developed under the agreement. The agreement follows Monsanto's initial testing of Tekmira's proprietary delivery technology and the demonstration of initial positive results from use of that technology in the field of agriculture, the company said.
News For TKMR;MON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
17:27 EDTTKMRTekmira files to sell $150M of common stock
November 25, 2014
10:53 EDTMONGMO seed makers limit launches as China slow on approvals, Reuters says
Seed companies like Syngenta (SYT), Dow AgroSciences (DOW) and Bayer (BAYRY) are altering their plans for new product launches as China has taken longer than usual to approve new GMO crops, says Reuters. Grain traders Cargill and Archer Daniels Midland (ADM) have already sued Syngenta, claiming the seed company misrepresented how long it would take to win Chinese approval for the seeds, added Reuters. Monsanto (MON) is another company in the seed business. Reference Link
November 20, 2014
15:14 EDTTKMRTraveler returned from Mali being tested for Ebola in NYC, Daily News reports
Subscribe for More Information
November 19, 2014
06:11 EDTTKMRTekmira to host analyst day
Analyst Day to be held in New York on November 21 at 9 am. Webcast Link
November 17, 2014
08:44 EDTTKMRNebraska Medical announces death of third Ebola patient
The Nebraska Medical Center said via Twitter, "We are sorry to announce that the 3rd Ebola patient, Dr. Martin Salia, has passed away as a result of the advanced symptoms of the disease." Drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Some companies that offer protective clothing and waste disposal include Lakeland Industries (LAKE), Alpha Pro Tech (APT) and Sharps Compliance (SMED).
08:12 EDTTKMRDicerna announces license agreement with Tekmira for PH1 program
Dicerna Pharmaceuticals (DRNA) announced a licensing agreement for Dicerna to use Tekmira’s (TKMR) proprietary lipid nanoparticle technology for delivery of DCR-PH1, Dicerna’s investigational product candidate for primary hyperoxaluria type 1, a rare, inherited liver disorder that often results in kidney failure, and for which there are no approved therapies. This announcement follows the successful testing of DCR-PH1 in combination with Tekmira's LNP technology in animal models, including mice and non-human primates. Under the agreement, Dicerna will pay Tekmira $2.5 million upfront, as well as $22 million in potential development milestones, and a mid-single-digit royalty on future PH1 sales. Tekmira’s LNP system has shown in other human clinical studies to provide potent, safe and effective RNA delivery to hepatocytes. Licensing Tekmira’s LNP will streamline the development path for DCR-PH1 and allows Dicerna to focus its LNP efforts on its oncology pipeline.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use